Business
Is Moderna stock a hold?
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
A recent downgrade from buy to hold from a Wall Street analyst has Moderna (NASDAQ: MRNA) stock under pressure. Needham analyst Alan Carr has removed his $110 price target on the stock, citing valuation concerns.
Moderna’s market cap has swelled 885% this year to around $67 billion at recent prices. Despite coming under pressure recently, this is still one of the best performing large-cap healthcare stocks of 2020.
Following a meeting on 17 December with the Food and Drug Administration’s independent advisory committee, Moderna’s coronavirus vaccine candidate MRNA-1273 will probably become the second vaccine to earn an…
-
Business16 hours agoThis ASX 200 healthcare stock crashed 14% to 4-year low. Here’s what happened
-
Business12 hours agoDicker Data rides the AI trend to double digit growth
-
Business20 hours agoThis leading broker thinks the CSL share price can climb 40%
-
Noosa News20 hours agoOld Translink app canned, and new version ‘worse than paper map from 2015’